Kargbo Robert B
API & DP Development, CMC Lead, Usona Institute, 2780 Woods Hollow Road, Madison, Wisconsin 53711, United States.
ACS Med Chem Lett. 2023 Aug 18;14(9):1134-1137. doi: 10.1021/acsmedchemlett.3c00333. eCollection 2023 Sep 14.
This viewpoint discusses integrating biomarkers, psychedelics, and AI into psychiatry for enhanced diagnostics, prognosis, and treatment. It highlights the potential of psychedelics in therapy, AI's role in predicting treatment response, and the challenges that must be addressed. The aim is to encourage research for more precise, personalized psychiatric care.
这一观点探讨了将生物标志物、迷幻剂和人工智能整合到精神病学中,以加强诊断、预后和治疗。它强调了迷幻剂在治疗中的潜力、人工智能在预测治疗反应中的作用以及必须应对的挑战。目的是鼓励开展研究,以提供更精确、个性化的精神科护理。